FBR Capital Downgrades Keryx Biopharmaceuticals (KERX) to Market Perform
Tweet Send to a Friend
FBR Capital downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Outperform to Market Perform with a price target of $7.00 (from $13.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE